MYBPC3 and chronic kidney disease: In contrast, comorbidities such as diabetes mellitus, CKD, PE, sepsis and COPD were not found to be associated with MyBP-C levels in our results, highlighting the additional potential role of this novel biomarker in these clinical situations.